Hims & Hers Health Plans To Bring Holistic Weight Loss Program To Canada, Timed With Anticipated Availability Of Generic Semaglutide Anywhere In World, Following ZAVA Acquisition Completion

-1.48%

Hims & Hers Health

HIMS

37.21

-1.48%

Entry to Canada will come as generic semaglutide hits the market for the first time, marking a major step in expanding access to affordable weight loss care

Hims & Hers Health, Inc. (NYSE:HIMS) the leading digital health and wellness platform, today announced its plans to bring its affordable, holistic weight loss program to Canada, timed with the anticipated first-ever availability of generic semaglutide anywhere in the world. This move follows the recent closing of the company's acquisition of ZAVA, the pioneering digital health platform in Europe.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.